COMPOSITION, INCLUDING ORIDONIN AND INTENDED FOR TREATMENT OF RESISTANT MALIGNANT TUMORS

摘要

1. The use of synergistically effective amounts of a compound having structural formula I! ! Formula I! Of its pharmaceutically acceptable salts and esters, selectively substituted analogs, or a combination of one or more of the above compounds with one or more compounds having structural formula II! ! Formula II! where R1 represents hydrogen, C1-C6 alkyl; R2 is hydrogen, C1-C6 alkyl or C2-C6 acyl and R3-R10 independently are hydrogen, hydroxyl group, C1-C6 alkyl, C1-C6 alkoxy or C2-C6 acyl, provided that at least four the substituents of R3-R10 are hydrogen, its pharmaceutically acceptable salts and esters, selectively substituted with analogues or a combination of one or more of the above compounds; and! compounds having structural formula IV! ! Formula IV! where R11-R14 independently represent hydrogen or C1-C6 alkyl and R15-R20 independently represent hydrogen, C1-C6 alkyl, C1-C6 alkoxy or C2-C6 acyl, provided that at least three substituents from R15- R20 are hydrogen, its pharmaceutically acceptable salts and esters, selectively substituted with analogues or a combination of one or more of the above compounds for the preparation of a medicament for the treatment of a therapeutic drug resistant neoplasia. ! 2. The use according to claim 1, where the neoplasia to be treated is selected from the group comprising prostate cancer, breast cancer, endometrial cancer, colon cancer, lung cancer, bladder cancer, testicular cancer, ovarian cancer, thyroid cancer �